Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Naveed Saleh, MD, MS

home / authors / naveed-saleh-md-ms

Articles

Advertisement

Study Compares Impact of Two Therapies on Survival in Squamous Cell Carcinoma

Study Compares Impact of Two Therapies on Survival in Squamous Cell Carcinoma

Naveed Saleh, MD, MS
March 11th 2019

Survival rates in patients with cSCC receiving high-dose chemoradiotherapy vs conventional radical surgery were compared.


Is NIFTP Truly a Non–Thyroid Cancer Diagnosis?

Is NIFTP Truly a Non–Thyroid Cancer Diagnosis?

Naveed Saleh, MD, MS
February 20th 2019

According to the American Thyroid Association guidelines, noninvasive follicular thyroid neoplasm with papillary-like features is benign.


Assessing Quality of Life After Thyroidectomy

Assessing Quality of Life After Thyroidectomy

Naveed Saleh, MD, MS
February 20th 2019

Researchers evaluated the incidence of physical, psychological, and lifestyle effects among patients with differentiated thyroid cancer.


The Microbiome and Colorectal Cancer: Current Clinical Trials

The Microbiome and Colorectal Cancer: Current Clinical Trials

Jennifer Leavitt, MS;Naveed Saleh, MD, MS
February 15th 2019

Here, we look at the currently open and recruiting clinical trials that focus on the role of the microbiome in colorectal cancer.


Trends in the Management of Non-Melanoma Skin Cancers

Trends in the Management of Non-Melanoma Skin Cancers

Naveed Saleh, MD, MS
February 15th 2019

A recent review article highlighted developments in the treatment of non-melanoma skin cancers, from new chemoprevention agents to telemedicine.


Is Indoor Tanning Linked to Melanoma and Non-Melanoma Skin Cancers?

Is Indoor Tanning Linked to Melanoma and Non-Melanoma Skin Cancers?

Naveed Saleh, MD, MS
February 14th 2019

A new meta-analysis offers compelling evidence on the causal relationship between indoor tanning and skin cancer risk.


Key Advances in Oncology, 2018

Key Advances in Oncology, 2018

Traci DeVito;Jennifer Leavitt, MS;Naveed Saleh, MD, MS
January 17th 2019

Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.


Oncology Conference Highlights, Q4

Oncology Conference Highlights, Q4

Jennifer Leavitt, MS;Traci DeVito;Naveed Saleh, MD, MS
January 17th 2019

Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.


Researchers ID Common Terminology to Describe Non-Melanoma Skin Cancers

Researchers ID Common Terminology to Describe Non-Melanoma Skin Cancers

Naveed Saleh, MD, MS
January 17th 2019

The findings of a systematic review may help standardize reflectance confocal microscopy terminology, which is used to describe non-melanocytic lesions.


Hope for New Apoptotic Regulatory Pathway in Treating Non-Melanoma Skin Cancers

Hope for New Apoptotic Regulatory Pathway in Treating Non-Melanoma Skin Cancers

Naveed Saleh, MD, MS
January 15th 2019

Researchers studied whether the mechanistic target of mTORC2 directs UVB–induced apoptosis by regulating the expression of NOXA downstream of FOXO3a.

Advertisement

Three Key Messages to Guide the Success of Oncology Biosimilars

Three Key Messages to Guide the Success of Oncology Biosimilars

Naveed Saleh, MD, MS
December 19th 2018

The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.


The Role of Biosimilars in Value-Based Oncology Care

The Role of Biosimilars in Value-Based Oncology Care

Naveed Saleh, MD, MS
December 19th 2018

Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?


Sizing Up Ultrasound-Based Risk-Stratification Systems for Thyroid Nodules

Sizing Up Ultrasound-Based Risk-Stratification Systems for Thyroid Nodules

Naveed Saleh, MD, MS
December 18th 2018

The performance of three international guidelines in detecting thryoid cancer was compared based on their sensitivity and fine-needle aspiration rates.


Promising New Prognostic Score for High-Risk DLBCL

Promising New Prognostic Score for High-Risk DLBCL

Naveed Saleh, MD, MS
December 18th 2018

Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.


Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018

Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018

Naveed Saleh, MD, MS
December 18th 2018

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.


TRIM29: A New Target in Treatment of Squamous Cell Carcinoma?

TRIM29: A New Target in Treatment of Squamous Cell Carcinoma?

Naveed Saleh, MD, MS
December 18th 2018

A new study in Cancer Research evaluated the function of TRIM29 in regulating keratin distribution and migration/invasion of SCC.


Do Larger Thyroid Tumors Mean Higher Rates of Malignancy and False-Negative FNA Results?

Do Larger Thyroid Tumors Mean Higher Rates of Malignancy and False-Negative FNA Results?

Naveed Saleh, MD, MS
December 17th 2018

The authors looked at whether rates of malignancy and false-negative fine-needle aspiration results are heightened in large thyroid nodules.


Comparing Field Treatment for Actinic Keratosis

Comparing Field Treatment for Actinic Keratosis

Naveed Saleh, MD, MS
December 12th 2018

Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.


Novel Immunotherapy for Primary Hemophagocytic Lymphohistiocytosis

Novel Immunotherapy for Primary Hemophagocytic Lymphohistiocytosis

Naveed Saleh, MD, MS
December 7th 2018

Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018.


Can Venetoclax Plus R-CHOP Improve Outcomes in Aggressive DLBCL?

Can Venetoclax Plus R-CHOP Improve Outcomes in Aggressive DLBCL?

Naveed Saleh, MD, MS
December 5th 2018

In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.

Advertisement

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients

Naveed Saleh, MD, MS
December 5th 2018

Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.


Acquired Mutation in BCL2 Confers Resistance to Tx in Progressive CLL

Acquired Mutation in BCL2 Confers Resistance to Tx in Progressive CLL

Naveed Saleh, MD, MS
December 4th 2018

Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.


Does Adding Daratumumab Benefit Transplant-Ineligible Myeloma Patients?

Does Adding Daratumumab Benefit Transplant-Ineligible Myeloma Patients?

Naveed Saleh, MD, MS
December 4th 2018

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.


multiple myeloma, proteasome inhibitor

Uncovering Novel Data on Myeloma Patients Treated With Proteasome Inhibitors

Naveed Saleh, MD, MS
December 3rd 2018

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.


New Combo Therapy Shows Promise in Leukemia

New Combo Therapy Shows Promise in Leukemia

Naveed Saleh, MD, MS
December 3rd 2018

Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.


Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients

Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients

Naveed Saleh, MD, MS
December 3rd 2018

Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.


A Better Risk Model for DLBCL Patients?

A Better Risk Model for DLBCL Patients?

Naveed Saleh, MD, MS
December 3rd 2018

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.


Single or Double Autologous Transplantation in New Myeloma Cases?

Single or Double Autologous Transplantation in New Myeloma Cases?

Naveed Saleh, MD, MS
December 2nd 2018

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.


multiple myeloma

Early Intervention With New Drug Combo Beneficial in Myeloma?

Naveed Saleh, MD, MS
November 30th 2018

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.


Allogeneic Transplantation in Elderly AML Patients

Allogeneic Transplantation in Elderly AML Patients

Naveed Saleh, MD, MS
November 30th 2018

Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.

<1234>

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: June 6th 2025
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.